Shilpa Biologicals signs co-development pact with Orion for Nivolumab biosimilar
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shilpa Biologicals, wholly owned subsidiary of Shilpa Medicare, signed a co-development and supply agreement with Finland based Orion Corporation for an intravenous Nivolumab biosimilar targeting Europe. Shilpa will lead development and manufacturing at its Dharwad facility; Orion will register, market and sell exclusively in Europe. Shilpa gets milestone payments plus supply revenue. Nivolumab targets a USD 4.1 billion PD-1 immunotherapy market.
Strategic partnership extension into immuno-oncology unlocks a large European market opportunity for Shilpa, supporting long-term revenue growth and validating its biologics capabilities.